Clinical Trials

A Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-0482 as monotherapy and in combination with pembrolizumab in participants with advanced/metastatic solid tumors.


Study ID
Merck MK-0482-001

NCT Number
NCT03918278 (Click on the NCT number for more information about the trial)

Research Study Number
2019-0154

Principle Investigator
Dr. Martin Gutierrez

Phase
I

Sponsor
Merck


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now